FIELD: medicine.
SUBSTANCE: group of inventions relates to medicine, in particular to oncology, and can be used for treating cancer. The method consists in introducing antagonist of a programmable cell death protein 1 (PD-1) and inhibitor indoleamine-2,3-dioxygenase 1 (IDO1), wherein the antagonist PD-1 is embodied in the form of a monoclonal antibody with heavy chains, each of which has an amino acid sequence SEQ ID NO: 21, and light chains, each of which has an amino acid sequence SEQ ID NO: 22; the IDO1 inhibitor is 4-({2-[(aminosulfonyl)amino]ethyl}amino)-N-(3-bromine-4-fluorophenyl)N'-hydroxy-1,2,5-oxadiazole-3-carboxumidamide or its pharmaceutically acceptable salt. The inventive drugs and kit also contain the above-mentioned PD-1 and IDO1.
EFFECT: use of the inventions enables increasing effectiveness of the treatment by means of anti-tumor activity of the combination and absence of serious side-reactions.
41 cl, 7 dwg, 5 tbl, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| TREATING CANCER WITH COMBINATION OF PD-1 ANTAGONIST AND DINACICLIB | 2014 |
|
RU2705795C2 |
| COMBINATION OF PD-1 ANTAGONIST AND ERIBULIN FOR TREATING CANCER | 2016 |
|
RU2737216C2 |
| METHODS OF TREATING CANCER USING ANTAGONISTS BINDING TO COMPONENTS OF THE SIGNAL PATH PD-1, AND TAXANES | 2014 |
|
RU2719487C2 |
| DOSAGE REGIMENS FOR ANTIBODIES AGAINST TIM-3 AND THEIR USE | 2018 |
|
RU2804775C2 |
| NOVEL APPROACH TO CANCER TREATMENT USING IMMUNOMODULATION | 2016 |
|
RU2817047C2 |
| NEW APPROACH TO TREATING CANCER WITH APPLICATION OF IMMUNOMODULATION | 2016 |
|
RU2711380C2 |
| ANTI-PD-L1 ANTIBODIES AND METHODS FOR THEIR DIAGNOSTIC USE | 2015 |
|
RU2715038C2 |
| ANTIBODY AGAINST PROGRAMMED CELL DEATH PROTEIN 1 (PD-1) AND APPLICATION THEREOF | 2015 |
|
RU2661678C1 |
| BIOMARKERS AND METHODS OF TREATING ASSOCIATED WITH PD-1 AND PD-L1 CONDITIONS | 2014 |
|
RU2701378C2 |
| METHODS OF TREATING CANCER USING PD-1 AXIS BINDING AND VEGF ANTAGONISTS | 2013 |
|
RU2689760C2 |
